Unichem Labs bags USFDA nod for hypertension drug Doxazosin
The product will be commercialized from Unichem's Goa Plant.
Mumbai: Unichem Laboratories Limited has announced that the Company has received Abbreviated New Drug Application (ANDA) approval for its Doxazosin Tablets USP, 1 mg, 2 mg, 4 mg and 8 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Cardura (Doxazosin) Tablets, 1 mg, 2 mg, 4 mg and 8 mg, of Viatris Specialty, LLC.
Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure.
According to the World Health Organisation (WHO), Hypertension (high blood pressure) is when the pressure in your blood vessels is too high (140/90 mmHg or higher). It is common but can be serious if not treated.
The product will be commercialized from Unichem’s Goa Plant.
Medical Dialogues team had earlier reported that Unichem Labs had received ANDA approval for its Labetalol Hydrochloride Tablets, USP 100 mg, 200 mg, and 300 mg from the USFDA.
Read also: Unichem Labs bags USFDA nod for Labetalol Hydrochloride Tablets
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd